Personal care composition

Abstract

Disclosed is a personal care composition comprising: (a) rosmarinic acid compound selected from rosmarinic acid, salt and ester thereof; and (b) retinoid, wherein the molar ratio of the total rosmarinic acid compound to the retinoid is at least 2.5:1.

Description

[0001] P0000933W01 CPL

[0002] 1

[0003] PERSONAL CARE COMPOSITION

[0004] Field of the Invention

[0005] The present invention relates to a personal care composition comprising (a) rosmarinic acid

[0006] 5 compound selected from rosmarinic acid, salt and ester thereof and (b) retinoid, wherein the molar ratio of the total rosmarinic acid compound to the retinoid is at least 2.5:1. It was surprisingly found that such composition is capable of significantly upregulating the expression of ELN gene.

[0007] Background of the Invention

[0008] The skin is a primary barrier of the human body. It protects the organs in the body from external stimulations. It is subject to intrinsic aging and extrinsic aging. Skin aging is a complex process, and alterations in human skin due to aging have distinct characteristics as compared to other organs. Characteristics of intrinsic or chronological skin aging include dryness, visible free lines and wrinkles, uneven skin pigmentation, loss of elasticity and skin sagging. Extrinsic factors

[0009] 15 including exposure to sunlight, pollutants and cigarette smoke can accelerate the skin aging process, especially on the face.

[0010] Elastin is a protein found naturally in the skin and encoded by the elastin (ELN) gene. The elastin is a key extracellular matrix protein that provides resilience and elasticity to the skin. It is highly

[0011] 20 elastic and present in connective tissue allowing skin to resume their shape after stretching or contracting. When people have enough elastin, the skin can stretch and compress as needed and then snap back to its original shape.

[0012] Unfortunately, elastin can degrade over time. The elastin fibers may become damaged, which

[0013] 25 means that the skin will not be able to rebound as well. Therefore, the present inventors have recognized that there is a need to develop solution to upregulate the expression of ELN gene to boost the production of elastin. It was surprisingly found that by combining rosmarinic acid compound and retinoid with a specific ratio, the expression of ELN gene was significantly upregulated.

[0014] Summary of the Invention

[0015] In a first aspect, the present invention is directed to a personal care composition comprising: (a) rosmarinic acid compound selected from rosmarinic acid, salt and ester thereof; and (b) retinoid, wherein the molar ratio of the total rosmarinic acid compound to the retinoid is at least 2.5:1 .

[0016] 35 P0000933W01 CPL

[0017] 2

[0018] In a second aspect, the present invention is directed to a method of providing the skin benefits selected from the group consisting of treating / preventing wrinkling, sagging, aged, dry, and / or photodamaged skin; boosting / maintaining elastin levels in skin; enhancing tissue repair; improving skin texture, smoothness and / or firmness; promoting skin barrier recovery; anti-aging;

[0019] 5 and / or upregulating the expression of elastin gene comprising a step of topically applying to the composition of the present invention.

[0020] In a third aspect, the present invention is directed to use of the composition of the present invention for providing the skin benefits selected from the group consisting of treating / preventing wrinkling, sagging, aged, dry, and / or photodamaged skin; boosting / maintaining elastin levels in skin; enhancing tissue repair; improving skin texture, smoothness and / or firmness; promoting skin barrier recovery; anti-aging; and / or upregulating the expression of elastin gene.

[0021] All other aspects of the present invention will more readily become apparent upon considering

[0022] 15 the detailed description and examples which follow.

[0023] Detailed Description of the Invention

[0024] Except in the examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material or conditions of reaction, physical properties of materials and / or

[0025] 20 use may optionally be understood as modified by the word “about”.

[0026] All amounts are by weight of the composition, unless otherwise specified.

[0027] It should be noted that in specifying any range of values, any particular upper value can be associated with any particular lower value.

[0028] For the avoidance of doubt, the word “comprising” is intended to mean “including” but not necessarily “consisting of’ or “composed of’. In other words, the listed steps or options need not be exhaustive.

[0029] 30

[0030] The disclosure of the invention as found herein is to be considered to cover all embodiments as found in the claims as being multiply dependent upon each other irrespective of the fact that claims may be found without multiple dependency or redundancy. P0000933W01 CPL

[0031] 3

[0032] Where a feature is disclosed with respect to a particular aspect of the invention (for example a composition of the invention), such disclosure is also to be considered to apply to any other aspect of the invention (for example a method of the invention) mutatis mutandis.

[0033] 5 Typically, the retinoid comprises retinyl ester, retinol, retinal, retinoic acid or a mixture thereof. More preferably the retinoid comprises retinol, retinyl ester, or a mixture thereof and even more preferably the retinoid is selected from retinol, retinyl ester, or a mixture thereof.

[0034] The term “retinol” includes the following isomers of retinol: all-trans-retinol, 13-cis-retinol, 11-cis- retinol, 9-cis-retinol, 3,4-didehydro-retinol, 3, 4-didehydro-13-cis-retinol; 3, 4-didehydro- 11 -cis- retinol; 3,4-didehydro-9-cis-retinol. Preferred isomers are selected from all-trans-retinol, 13-cis- retinol, 3,4-didehydro-retinol, and 9-cis-retinol. Most preferred retinol is all-trans-retinol, due to its wide commercial availability.

[0035] 15 Retinyl ester is an ester of retinol. The term “retinol” has been defined above. Retinyl esters suitable for use in the present invention are preferably C1-C30 esters of retinol, more preferably C2-C20 esters of retinol, and most preferably C2, C3, and C16 esters of retinol. Examples of retinyl esters comprises retinyl palmitate, retinyl formate, retinyl acetate, retinyl propionate, retinyl butyrate, retinyl valerate, retinyl isovalerate, retinyl hexanoate, retinyl heptanoate, retinyl

[0036] 20 octanoate, retinyl nonanoate, retinyl decanoate, retinyl undecanoate, retinyl laurate, retinyl tridecanoate, retinyl myristate, retinyl pentadecanoate, retinyl heptadecanoate, retinyl stearate, retinyl isostearate, retinyl nonadecanoate, retinyl arachidonate, retinyl behenate, retinyl linoleate, retinyl oleate or a combination thereof. The retinyl ester for use in the present invention is preferably selected from retinyl palmitate, retinyl acetate, retinyl linoleate, retinyl oleate, retinyl

[0037] 25 propionate or a mixture thereof. More preferably the retinyl ester is selected from retinyl palmitate, retinyl acetate, retinyl propionate, or a mixture thereof. Most preferably the retinyl ester is selected from retinyl palmitate, retinyl propionate, or a mixture thereof.

[0038] Particularly preferred retinoid is selected from all-trans-retinol, retinyl palmitate, retinyl acetate, retinyl propionate, or a mixture thereof. Most preferably the retinoid is selected from retinyl palmitate, retinyl propionate, or a mixture thereof.

[0039] Preferably, retinoid is employed in the composition in an amount of 0.0001 to 20% by weight of the composition, more preferably in an amount of 0.005 to 15%, even more preferably in an

[0040] 35 amount of 0.2 to 12%, still even more preferably from 1 to 8%, and most preferably 2 to 6% by P0000933W01 CPL weight of the composition. Preferably, the total amount of retinol and retinyl ester is 0.0001 to 20% by weight of the composition, more preferably in an amount of 0.005 to 15%, even more preferably in an amount of 0.2 to 12%, still even more preferably from 1 to 8%, and most preferably 2 to 6% by weight of the composition. Preferably, the total amount of retinyl palmitate,

[0041] 5 retinyl propionate is 0.0001 to 20% by weight of the composition, more preferably in an amount of 0.005 to 15%, even more preferably in an amount of 0.2 to 12%, still even more preferably from 1 to 8%, and most preferably 2 to 6% by weight of the composition.

[0042] The composition of the present invention comprises rosmarinic acid compound selected from rosmarinic acid, salt and ester thereof.

[0043] Preferably the rosmarinic acid compound has the following formula (I):

[0044] 15 wherein Ri, R2, R4, Rs is independently, hydrogen or C1-6 alkyl chain, and R3 is hydrogen or C1-24 alkyl chain. More preferably, the rosmarinic acid compound has the formula (I), wherein R1, R2, R4, Rs is independently, hydrogen or methyl, and R3 is hydrogen or C1-12 alkyl chain. Even more preferably the rosmarinic acid compound has the formula (I), wherein R1, R2, R4, Rs is

[0045] 20 independently, hydrogen or methyl and R3 is hydrogen or C1-6 alkyl chain. Still even more preferably the rosmarinic acid compound has the formula (I), wherein R1, R2, R4, Rs is hydrogen and R3is hydrogen or C1-6 alkyl chain. Most preferably the rosmarinic acid compound has the formula (I), wherein R1, R2, R3, R4, Rs are all hydrogen.

[0046] 25 Preferably, the rosmarinic acid compound is selected from rosmarinic acid and salt thereof. More preferably, the rosmarinic acid compound is rosmarinic acid.

[0047] Preferably, the ester of rosmarinic acid has formula (I) wherein R1, R2, R4, Rs is independently, hydrogen or methyl and R3 is C1-24 alkyl chain. More preferably, the ester of rosmarinic acid has

[0048] 30 formula (I) wherein R1, R2, R4, Rs are all hydrogen and R3 is C1-24 alkyl chain. Even more preferably, P0000933W01 CPL

[0049] 5 the ester of rosmarinic acid has formula (I) wherein Ri, R2, R4, Rs are all hydrogen and R3is Ci- 12 alkyl chain, preferably C1-6 alkyl chain. Salt of the rosmarinic acid especially comprises Mg, Na, K and / or Ca salts of rosmarinic acid. It is preferred that the salt of rosmarinic acid is sodium salt of rosmarinic acid.

[0050] 5

[0051] The amount of the rosmarinic acid compound is preferably in the range of 0.00001 to 10%, more preferably from 0.0001 to 5%, even more preferably from 0.005 to 3%, still even more preferably from 0.05 to 1.5%, most preferably from 0.1 to 0.8% by weight of the total amount of the composition. The amount of the rosmarinic acid and salt thereof is preferably in the range of 0.0001 to 10%,

[0052] 10 more preferably from 0.001 to 5%, even more preferably from 0.005 to 3%, still even more preferably from 0.05 to 1.5%, most preferably from 0.1 to 0.8% by weight of the total amount of the composition. The amount of the rosmarinic acid is preferably in the range of 0.0001 to 10%, more preferably from 0.001 to 5%, even more preferably from 0.005 to 3%, still even more preferably from 0.05 to 1.5%, most preferably from 0.1 to 0.8% by weight of the total amount of the composition.

[0053] 15

[0054] The rosmarinic acid compound may be provided by extract, preferably by rosemary extract. Preferably, the rosemary extract is an aqueous extract. The term “aqueous extract” means that the extract is obtained by using water, or water mixing with hydrophilic organic solvent as the solvent for extraction. The hydrophilic organic solvent may be selected from C1-C5 alcohol (including

[0055] 20 polyalcohol), C3-C6 aliphatic ketone; and C2-C5 polyalcohol. Preferably the hydrophilic organic solvent is selected from ethanol, acetone, ethyl acetate, glycerin, isoprene glycol, butylene glycol or a mixture thereof. However, it is preferable that the extract is obtained by solely using water, or water mixing ethanol, acetone and / or glycerin as solvent for extraction. Preferably, the extract is solid at 25°C and atmospheric pressure.

[0056] 25

[0057] Preferably, the molar ratio of the total rosmarinic acid compound to the retinoid is 2.5:1 to 300:1 , more preferably 3:1 to 100:1 , even more preferably 3:1 to 50:1 , still even more preferably 8:1 to 30: 1 . Preferably, the molar ratio of the total rosmarinic acid and salt thereof to the retinoid is 2.5: 1 to 300: 1 , more preferably 3: 1 to 100: 1 , even more preferably 3: 1 to 50: 1 , still even more preferably

[0058] 30 8:1 to 30:1. Preferably, the molar ratio of the total rosmarinic acid and salt thereof to the total retinyl palmitate and retinyl propionate is 2.5:1 to 300:1 , more preferably 3:1 to 100:1 , even more preferably 3:1 to 50:1 , still even more preferably 8:1 to 30:1. Preferably, the molar ratio of the rosmarinic acid to the total retinyl palmitate and retinyl propionate is 2.5:1 to 300:1 , more preferably 3:1 to 100:1 , even more preferably 3:1 to 50:1 , still even more preferably 8:1 to 30:1. P0000933W01 CPL

[0059] 6

[0060] The composition may comprise substituted resorcinol. Substituted resorcinol typically refers to that at least one hydrogen on the ring structure and / or on a hydroxy group of the resorcinol replaced with an alkyl group, phenyl alkyl group, or heterocyclic group. Preferably, the substituted resorcinol is 4-substituted resorcinol. Preferably, the substituted resorcinol is selected from 4-

[0061] 5 ethyl resorcinol, 4-butyl resorcinol, 4-hexyl resorcinol, phenylethyl resorcinol, thiamidol, or a mixture thereof, more preferably, the substituted resorcinol is selected from 4-ethyl resorcinol, 4- butyl resorcinol, 4-hexyl resorcinol, or a mixture thereof and even more preferably, the substituted resorcinol comprises 4-hexyl resorcinol. The amount of the substituted resorcinol is preferably in the range of 0.00001 to 10%, more preferably from 0.001 to 5% and most preferably from 0.1 to 0.6% by weight of the total amount of the composition.

[0062] Preferably, the composition comprises Vitamin B3 compounds (including derivatives of vitamin B3). The vitamin B3 compounds comprises niacin, nicotinic acid, niacinamide or a mixture thereof. The most preferred vitamin B3 compound is niacinamide. Amount of Vitamin B3 compounds may

[0063] 15 be 0.1 to 10%, preferably 0.5 to 5% by weight of the composition. 2-mercaptonicotinoyl glycine may also be included in the composition. Amount of 2-mercaptonicotinoyl glycine may be 0.0001 to 10%, preferably 0.01 to 1 % by weight of the composition.

[0064] Preferably, the composition comprises a glutamate source selected from the group consisting of

[0065] 20 glutamine, glutamine ester, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and / or salt of pyroglutamic acid. Even more preferably, the composition comprises sodium salt of pyroglutamic acid. Preferably, the glutamate source is present in amount of 0.0001 to 10% by weight of the composition, more preferably 0.001 to 6%, even more preferably 0.01 to 3% by weight of the composition.

[0066] 25

[0067] The composition may optionally comprise whitening pigment. Whitening pigments are typically particles of high refractive index materials. For example, the whitening pigment may have a refractive index of greater than 1.3, more preferably greater than 1.8 and most preferably from 2.0 to 2.7. Examples of such whitening pigment are those comprising bismuth oxy-chloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminium oxide, zinc oxide or combinations thereof. More preferred whitening pigment are particles comprising titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide or a combination thereof. Even more preferred whitening pigment are particles comprising zinc oxide, zirconium oxide, titanium dioxide or a combination thereof as these materials have especially high refractive index. Still even more

[0068] 35 preferably the whitening pigment is selected from titanium dioxide, zinc oxide or a mixture thereof P0000933W01 CPL

[0069] 7 and most preferred whitening pigment is titanium dioxide. The average diameter of whitening pigment is typical from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm and still even more preferably from 100 to 300 nm. Amount of whitening pigment may be 0.1 to 15%, preferably 0.5 to 5% by weight of the composition.

[0070] 5

[0071] Preferably, the composition comprises polyhydric alcohol. Polyhydric alcohols may be selected from group of glycerin, propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1 ,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or a mixture thereof. Most preferred polyhydric alcohol is glycerol known also as glycerin. The amount of polyhydric alcohol may range anywhere from 0.1 to 20%, preferably 0.5 to 15% and more preferably 2 and 10% by weight of the composition.

[0072] Preferably, the composition comprises emollient materials. Suitable emollient materials include silicones, hydrocarbons, triglycerides or a mixture thereof. These silicones may be organic,

[0073] 15 silicone-containing or fluorine-containing, volatile or non-volatile, polar or non-polar. Hydrocarbons may include mineral oil, petrolatum and polyalpha-olefins. Examples of preferred volatile hydrocarbons include polydecanes such as isododecane and isodecane (e.g. Permethyl- 99A which is available from Presperse Inc.) and the CyCs through C12-C15 isoparaffins (such as the Isopar Series available from Exxon Chemicals). Illustrative triglycerides but not limiting are

[0074] 20 sunflower seed oil, cotton oil, canola oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil and mixtures thereof. Mono- and di- glycerides may also be useful. Particularly preferable are glyceryl monostearate and glyceryl distearate.

[0075] Preferably, the composition comprises moisturizing agents. Particularly preferred moisturizing agents includes, petrolatum, aquaporin manipulating actives, oat kernel flour, substituted urea like hydroxyethyl urea, hyaluronic acid and / or its precursor N-acetyl glucosamine, hyaluronic acid and / or its precursor N-acetyl glucosamine, or a mixture thereof.

[0076] Some compositions may include thickeners. These may be selected from cellulosics, natural

[0077] 30 gums and acrylic polymers but not limited by this thickening agent types. Among the cellulosics are sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof. Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof. Among the acrylic thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, llltrez, Aqua P0000933W01 CPL

[0078] 8

[0079] SF-1 and Aqua SF-2 available from the Lubrizol Corporation. Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the compositions.

[0080] In addition, the compositions of the invention may further include 0.5 to 10% by weight of

[0081] 5 sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene / Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.

[0082] The composition may comprise water in amount of 10 to 96% by weight of the composition, more preferably from 25 to 92%, even more preferably from 42 to 88%, most preferably from 55 to 82% by weight of the composition.

[0083] Preferably, the composition has a viscosity of at least 10 mPa s, more preferably in the range 30

[0084] 15 to 10000 mPa s, even more preferably 50 to 5000 mPa s, and most preferably 100 to 2000 mPa s, when measured at 20 degrees C at a relatively high shear rate of about 20 s-1.

[0085] Preferably, the composition is an emulsion, more preferably an oil-in-water emulsion. Preferably the composition is a fluid liquid at 25 °C and atmospheric pressure.

[0086] 20

[0087] Preferably, the composition is an emulsion, more preferably an oil-in-water emulsion. Preferably, the personal care composition is a skin care composition. The skin care composition refers to a composition suitable for topical application to human skin, including leave-on and wash-off products but preferably leave-on compositions. The term “leave-on” as used with reference to

[0088] 25 compositions herein means a composition that is applied to or rubbed on the skin and left thereon. The term “wash-off” as used with reference to compositions herein means a skin cleanser that is applied to or rubbed on the skin and rinsed off substantially immediately subsequent to application. Preferably the composition is a fluid liquid, and particularly a moisturizer rather than a make-up product. The term "skin" as used herein includes the skin on the face, neck, chest, abdomen, back, arms, under arms, hands, and legs. Preferably “skin” means includes the skin on the face and under arms, more preferably skin means skin on the face other than lips and eyelids.

[0089] Preferably, the composition is a topical composition. Preferably, the composition may be in the

[0090] 35 form of cream, lotion, ointment, solution, suspension, emulsion, paste, gel, powder, powder P0000933W01 CPL

[0091] 9 foundation, emulsion foundation, wax foundation, or spray. More preferably, the composition may be formulated in the form of cream, lotion, ointment, emulsion, gel, or a spray.

[0092] Preferably, the composition is capable of upregulating the expression of ELN gene by at least 1 .2

[0093] 5 fold change, more preferably 1.4 to 8 and most preferably 1.6 to 4 and most preferably 1.8 to 3 fold change, typically in comparison to personal care composition comprising rosmarinic acid compound selected from rosmarinic acid, salt and ester thereof alone, or retinoid alone, or in comparison to personal care composition containing rosmarinic acid compound selected from rosmarinic acid, salt and ester thereof and retinoid with molar ratio of the total rosmarinic acid compound to the retinoid of 1 :1.

[0094] Preferably the use is non-therapeutic. Preferably the method is non-therapeutic. The term non- therapeutic typically means for cosmetic purposes and not curative or therapeutic purposes.

[0095] 15 The following examples are provided to facilitate an understanding of the invention. The examples are not intended to limit the scope of the claims.

[0096] 20 Example 1

[0097] This example demonstrates the improved ELN gene expression by combining retinyl propionate and rosmarinic acid in a specific ratio.

[0098] The normal human dermal fibroblasts (NHDF) (Biocell, Xi’an, China, Lot: Fb19052002) were

[0099] 25 incubated in medium together with or without actives for 48 hours. After incubation, the total RNA for each NHDF was extracted using RNAiso Plus (Takara Bio USA, Inc., Cat: 9109) according to manufacturer’s protocol.

[0100] The extracted RNA was quantified using Nanodrop spectrometer (Thermo Fisher Scientific, Waltham, MA, US) and reverse transcribed to generate the template cDNA using the PrimeScript™ RT Master Mix (Takara Bio USA, Inc., Cat: RR036A) according to manufacturer’s protocol. Gene expression of ELN was analyzed by quantitative polymerase chain reaction (PCR) using TB Green® Premix Ex Taq™ II (Tli RNase H Plus) (Takara Bio USA, Inc., Cat: RR820A). The actin bata (ACTS) gene was selected as the housekeeping gene and all data on relative

[0101] 35 expression of the target genes was normalized to ACTB gene. The fold changes in expression P0000933W01 CPL

[0102] 10 were calculated relative to the blank control (medium having no active). All tests were conducted at least three times and Table 1 shows the fold changes in expression of ELN gene.

[0103] Table 1

[0104] *The level of the ingredients refers the level of active based on the medium. a: Rosmarinic acid, supplied by Shanghai Tauto Biotech Co., Ltd. b: Retinyl propionate, cat no.: sc-236667, supplied by Santa Cruz Biotechnology (USA) c: Lower than the product of fold changes of A and B.

[0105] 10 d: Significantly higher than the product of fold changes of A and C (p < 0.05). e: Significantly higher than the product of fold changes of A and D (p < 0.05).

[0106] It was evident from Table 1 that only when combining rosmarinic acid and retinyl propionate in a specific molar ratio of the present invention, the expression of ELN gene is synergistically 15 upregulated (1 and 2). In contrast, when combining rosmarinic acid and retinyl propionate in a molar ratio not within the range of the present invention, the expression of ELN gene is not upregulated (E).

Claims

P0000933W01 CPL11Claims1. A personal care composition comprising:(a) rosmarinic acid compound selected from rosmarinic acid, salt and ester thereof; and(b) retinoid, wherein the molar ratio of the total rosmarinic acid compound to the retinoid is at least 2.5:1 and the composition comprises water in amount of 10 to 96% by weight of the composition.

2. The composition according to claim 1 wherein the retinoid comprises retinol, retinyl ester, or a mixture thereof, preferably the retinoid is selected from retinyl palmitate, retinyl propionate, or a mixture thereof.

3. The composition according to claim 1 or 2 wherein the retinoid is employed in the composition in an amount of 0.0001 to 20% by weight of the composition, preferably in an amount of 0.2 to 12% by weight of the composition.

4. The composition according to any one of the preceding claims wherein the ester of rosmarinic acid has formula (I):wherein Ri, R2, R4, Rs is independently, hydrogen or methyl and R3 is C1-24 alkyl chain.

5. The composition according to any one of the preceding claims the rosmarinic acid compound is selected from rosmarinic acid and salt thereof, preferably the rosmarinic acid compound is rosmarinic acid.

6. The composition according to any one of the preceding claims wherein the rosmarinic acid compound is provided by rosemary extract.P0000933W01 CPL127. The composition according to any one of the preceding claims wherein the amount of the rosmarinic acid compound is in the range of 0.00001 to 10%, preferably from 0.005 to 3% by weight of the total amount of the composition.

8. The composition according to any one of the preceding claims wherein the molar ratio of the total rosmarinic acid compound to the retinoid is 2.5:1 to 300:1 , preferably 3:1 to 50:1.

9. The composition according to any one of the preceding claims wherein the composition is an emulsion, preferably an oil-in-water emulsion.

10. The composition according to any one of the preceding claims wherein the composition is a fluid liquid at 25 °C and atmospheric pressure.11 . The composition according to any one of the preceding claims wherein the composition comprises water in amount of 42 to 88% by weight of the composition.

12. A method of providing the skin benefits selected from the group consisting of treating / preventing wrinkling, sagging, aged, dry, and / or photodamaged skin; boosting / maintaining elastin levels in skin; enhancing tissue repair; improving skin texture, smoothness and / or firmness; promoting skin barrier recovery; anti-aging; and / or upregulating the expression of elastin gene comprising a step of topically applying to the composition of any one of the preceding claims 1 to 11.

13. Use of the composition of any one of the preceding claims 1 to 11 for providing the skin benefits selected from the group consisting of treating / preventing wrinkling, sagging, aged, dry, and / or photodamaged skin; boosting / maintaining elastin levels in skin; enhancing tissue repair; improving skin texture, smoothness and / or firmness; promoting skin barrier recovery; anti-aging; and / or upregulating the expression of elastin gene.

Images